“Crohn’s Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn’s Disease Market.
Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).
Some of the key takeaways from the Crohn’s Disease Pipeline Report:
Companies across the globe are diligently working toward developing novel Crohn’s Disease treatment therapies with a considerable amount of success over the years.
Crohn’s Disease companies working in the treatment market are Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others, are developing therapies for the Crohn’s Disease treatment
Emerging Crohn’s Disease therapies in the different phases of clinical trials are- MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others are expected to have a significant impact on the Crohn’s Disease market in the coming years.
In May 2024, In Eli Lilly and Company’s (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderate to severe Crohn’s disease, regardless of prior biologic treatment failure, experienced statistically significant and clinically meaningful improvements in various clinical and endoscopic measures after one year of treatment with mirikizumab compared to placebo.
In March 2024, Developed by Janssen Biotech, Stelara is a biologic therapy used to treat various conditions, such as moderate to severely active Crohn’s disease, active ulcerative colitis (UC), active psoriatic arthritis, and plaque psoriasis. It can be administered either subcutaneously or intravenously. The subcutaneous injection comes in two formulations: 45mg/0.5ml and 90mg/ml, both available in single-dose prefilled syringes.
In May 2023, For those with moderate to severe active Crohn’s disease who did not respond well to or were intolerant of one or more tumour necrosis factor blockers, the FDA has approved Rinvoq (upadacitinib). The first oral medicine for the management of Crohn’s disease that has received FDA approval is called Rinvoq.
Crohn’s Disease Overview
Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, causing inflammation anywhere from the mouth to the anus, but most commonly in the small intestine and the beginning of the large intestine (colon). It belongs to a group of conditions known as inflammatory bowel diseases (IBD).
Get a Free Sample PDF Report to know more about Crohn’s Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/crohns-disease-cd-pipeline-insight
Emerging Crohn’s Disease Drugs Under Different Phases of Clinical Development Include:
MORF 057: Morphic Therapeutic
OTL-104: Orchard Therapeutics
TP-317: Thetis Pharmaceuticals
AZD 7798: AstraZeneca
IMU 856: Immunic
CBP-307: Suzhou Connect Biopharmaceuticals
PF-06651600: Pfizer
Deucravacitinib: Bristol-Myers Squibb
E6011: Eisai Inc
Guselkumab: Janssen Pharmaceutical
Mirikizumab: Eli Lilly and Company
Filgotinib: Gilead Sciences
RHB-104: RedHill Biopharma
Ozanimod: Celgene Corporation
Brazikumab: AstraZeneca
Crohn’s Disease Route of Administration
Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Crohn’s Disease Molecule Type
Crohn’s Disease Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Crohn’s Disease Pipeline Therapeutics Assessment
Crohn’s Disease Assessment by Product Type
Crohn’s Disease By Stage and Product Type
Crohn’s Disease Assessment by Route of Administration
Crohn’s Disease By Stage and Route of Administration
Crohn’s Disease Assessment by Molecule Type
Crohn’s Disease by Stage and Molecule Type
DelveInsight’s Crohn’s Disease Report covers around 80 + products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Crohn’s Disease product details are provided in the report. Download the Crohn’s Disease pipeline report to learn more about the emerging Crohn’s Disease therapies
Some of the key companies in the Crohn’s Disease Therapeutics Market include:
Key companies developing therapies for Crohn’s Disease are – Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, and others.
Crohn’s Disease Pipeline Analysis:
The Crohn’s Disease pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
Crohn’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Crohn’s Disease drugs and therapies
Crohn’s Disease Pipeline Market Drivers
High prevalence of Crohn’s Disease, increase in Drug Development for Crohn’s treatment, change in lifestyle patterns are some of the important factors that are fueling the Crohn’s Disease Market.
Crohn’s Disease Pipeline Market Barriers
However, lack of early diagnosis of the disease, high cost associated with the treatment and other factors are creating obstacles in the Crohn’s Disease Market growth.
Scope of Crohn’s Disease Pipeline Drug Insight
Coverage: Global
Key Crohn’s Disease Companies: Morphic Therapeutic, Orchard Therapeutics, Thetis Pharmaceuticals, AstraZeneca, Immunic, Suzhou Connect Biopharmaceuticals, Pfizer, Bristol-Myers Squibb, Eisai Inc, Janssen Pharmaceutical, Eli Lilly and Company, Gilead Sciences, RedHill Biopharma, Celgene Corporation, AstraZeneca, and others
Key Crohn’s Disease Therapies: MORF 057, OTL-104, TP-317, AZD 7798, IMU 856, CBP-307, PF-06651600, Deucravacitinib, E6011, Guselkumab, Mirikizumab, Filgotinib, RHB-104, Ozanimod, Brazikumab, and others
Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies
Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers
Request for Sample PDF Report for Crohn’s Disease Pipeline Assessment and clinical trials
Table of Contents
1. Crohn’s Disease Report Introduction
2. Crohn’s Disease Executive Summary
3. Crohn’s Disease Overview
4. Crohn’s Disease- Analytical Perspective In-depth Commercial Assessment
5. Crohn’s Disease Pipeline Therapeutics
6. Crohn’s Disease Late Stage Products (Phase II/III)
7. Crohn’s Disease Mid Stage Products (Phase II)
8. Crohn’s Disease Early Stage Products (Phase I)
9. Crohn’s Disease Preclinical Stage Products
10. Crohn’s Disease Therapeutics Assessment
11. Crohn’s Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Crohn’s Disease Key Companies
14. Crohn’s Disease Key Products
15. Crohn’s Disease Unmet Needs
16 . Crohn’s Disease Market Drivers and Barriers
17. Crohn’s Disease Future Perspectives and Conclusion
18. Crohn’s Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
